BioSpace News Archive

Amarin Corporation plc, announced today that BioNJ awarded Amarin with an Innovator Award in recognition of the approval of a new indication for VASCEPA® by the U.S. Food and Drug Administration in December 2019.

MOORESTOWN, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), a healthcare technology company advancing the field of medication safety, will release its fourth quarter and full year 2019 operating results on Thursday, February 27, 2020 after market close, on the investor relations section of TRHC’s website at ir.trhc.com . A conference call hosted by Chairman and CEO, Calvin H. Knowlton, Ph.D., President and Chief Marketing and Business Development Officer, O

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, February 13, 2020 at 4:30 p.m. Eastern time to discuss the financial results for the fourth quarter and year ended December 31, 2019.

FDA grants Type C meeting for SB206 to be held on April 1, 2020 Last subject completes last visit, Week 24 safety evaluation Additional 12-week efficacy and safety data provided MORRISVILLE, N.C., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today provided an update on several aspects of its Phase 3 B-SIMPLE program (B-SIMPLE1 and B-SIMPLE2). Novan has been granted a Type C meeting with the U.S. Food and Drug Administration (“FDA”) on Apri

Feb. 6, 2020 13:30 UTC KEARNEY, Neb.--( BUSINESS WIRE )-- SCORR Marketing , a global health science communications firm, has released a life sciences industry salary and employee satisfaction survey report. Produced with Applied Clinical Trials , this free information is unavailable elsewhere. It will help drug development and clinical research employers improve retention in an industry with significant employee turnover and help employees negotiate contracts.

Feb. 6, 2020 13:30 UTC IRVINE, Calif.--( BUSINESS WIRE )-- Endologix, Inc. (the “Company”) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the fourth quarter ended December 31, 2019 is expected to be approximately $35.8 million. Revenue for the full year ended December 31, 2019 is expected to be approximately $143.4 million.

Survival outcomes for HPV-positive oropharyngeal squamous cell carcinoma of the head and neck (SCCHN) have made significant gains in recent years, but new research in the February 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds some groups are being left behind.

LogixHealth has released its 2020 Emergency Department Physician Update, a comprehensive review of Medicare’s 2020 Physician Fee Schedule Final Rule.

Moleculin Biotech, Inc., (NASDAQ: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that it has entered into definitive agreements with institutional investors to purchase an aggregate of up to 7,500,000 shares

As healthcare costs continue to rise in 2020, Valpak, a leader in local print and digital marketing, recently announced a new way to help their customers save on prescription drugs: ValpakRx.